Molecular diagnosis of the myeloproliferative neoplasms: UK guidelines for the detection ofJAK2V617F and other relevant mutations-Reference-Cited by-同舟云学术

Molecular diagnosis of the myeloproliferative neoplasms: UK guidelines for the detection ofJAK2V617F and other relevant mutations

Published:2012-10-11 Issue:1 Volume:160 Page:25-34
ISSN:0007-1048
Container-title:British Journal of Haematology
language:en
Short-container-title:Br J Haematol

Author:

Bench Anthony J.¹,White Helen E.,Foroni Letizia²,Godfrey Anna L.³,Gerrard Gareth²,Akiki Susanna⁴,Awan Abida⁵,Carter Ian⁶,Goday-Fernandez Andrea¹,Langabeer Stephen E.⁷,Clench Tim⁸,Clark Jordan⁹,Evans Paul A.¹⁰,Grimwade David¹¹,Schuh Anna¹²,McMullin Mary F.¹³,Green Anthony R.³,Harrison Claire N.¹⁴,Cross Nicholas C. P.

Affiliation:

1. Molecular Malignancy Laboratory and Haemato-Oncology Diagnostic Service; Cambridge University Hospitals NHS Foundation Trust; Cambridge; UK

2. Imperial Molecular Pathology; Imperial College Academic Health Science Centre; London; UK

3. Cambridge Institute for Medical Research; Department of Haematology; University of Cambridge; Cambridge; UK

4. West Midlands Regional Genetics Laboratory; Birmingham Women's NHS Foundation Trust; Birmingham; UK

5. Molecular Diagnostics Centre; Manchester Royal Infirmary; Manchester; UK

6. Nottingham University Hospitals NHS Trust; Nottingham; UK

7. Cancer Molecular Diagnostics; St. James's Hospital; Dublin; Ireland

8. Bristol Royal Infirmary; Bristol; UK

9. UK NEQAS for Leucocyte Immunophenotyping; Sheffield; UK

10. HMDS, Leeds Institute of Oncology; St. James's University Hospital; Leeds; UK

11. Department of Medical and Molecular Genetics; King's College London School of Medicine; London; UK

12. Oxford Cancer and Haematology Centre; Churchill Hospital; Oxford; UK

13. Belfast City Hospital; Queen's University Belfast; Belfast; UK

14. Guy's and St Thomas' NHS Foundation Trust; Guy's Hospital; London; UK

Publisher

Wiley

Subject

Hematology

Link

http://onlinelibrary.wiley.com/wol1/doi/10.1111/bjh.12075/fullpdf

Reference87 articles.

1. A new TMHA-DHPLC assay for the rapid mutation screening of JAK2 exon 14 in myeloproliferative disorders;Albiero;American Journal of Hematology,2008

2. Hydroxyurea does not appreciably reduce JAK2 V617F allele burden in patients with polycythemia vera or essential thrombocythemia;Antonioli;Haematologica,2010

3. Interstitial deletion constitutes the major mechanism for loss of heterozygosity on chromosome 20q in polycythemia vera;Asimakopoulos;Blood,1996

4. Acquired mutation of the tyrosine kinase JAK2 in human myeloproliferative disorders;Baxter;Lancet,2005

5. MPL mutations in myeloproliferative disorders: analysis of the PT-1 Cohort;Beer;Blood,2008

Cited by 83 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Superior detection of low-allele burden Janus kinase 2 V617F mutation and monitoring clonal evolution in myeloproliferative neoplasms using chip-based digital PCR;Annals of Hematology;2024-07-24

2. DÜŞÜK VE YÜKSEK JAK2V617F ALLEL YÜKÜ OLAN MİYELOPROLİFERATİF NEOPLAZİ ÖN TANILI HASTALARIN KLİNİK VE HEMATOLOJİK PARAMETRELER AÇISINDAN KARŞILAŞTIRILMASI;Kocatepe Tıp Dergisi;2024-01-17

3. A Review on the Role of Molecular Genetics in the Diagnostic Workup of BCR::ABL1-Negative Myeloproliferative Neoplasms;Indian Journal of Medical and Paediatric Oncology;2023-04-17

4. Clonal hematopoiesis and cardiovascular diseases: role of JAK2V617F;Journal of Cardiology;2023-01

5. Clinical utility of liquid biopsy and integrative genomic profiling in early-stage and oligometastatic cancer patients treated with radiotherapy;British Journal of Cancer;2022-12-22